Muse will combine de novo design with multicriteria optimization.

Tripos International and AstraZeneca are joining forces to create a new drug discovery workflow solution. The focus will be on the development of Tripos’ Muse™ de novo design product, which is expected to be commercially available later this year.

Muse is being designed to accelerate the identification and optimization of lead candidates on Tripos’ Pantheon™ platform. It combines de novo design with multicriteria optimization.

It is anticipated that Muse will permit researchers to find structures, scaffolds, or side-chains that meet specific design objectives. Modelers will be able to quickly and easily generate ideas for new side chains that optimize a panel of biological and ADME properties, preserve key R-groups, and invent new scaffolds, the companies explain.

Previous articleNovozymes Awarded $12.3M to Augment Enzymes Used in Cellulosic Ethanol
Next articleResearchers Show How GluR1 Controls Dendritic Growth Early in Development